Dr. Mikhail Blagosklonny is a distinguished physician-scientist who studied aging and cancer. Currently, he is a professor of oncology at Roswell Park Institute, New York. In his education life, Blagosklonny received a master degree in internal medicine. He then went ahead to earn a Ph.D. in cardiology and experimental medicine from the First Pavlov Medical University of St. Petersburg. He was also given the position of an associate professor of medicine at the New York Medical College. He then rose to the position of a senior scientist at Ordway Research Institute, which he held until 2009.
Blagasklonny interest in research includes targeted cancer and cancer therapies that can protect the normal cell from damage, as well as anti-aging drugs and underlying mechanisms for aging. According to the result of the research, Blagasklonny has managed to formulate a hypothesis describing the possible role of TOR (Target of rapamycin) signaling in cancer and aging. In the hypothesis, he proposed the use of rapamycin, which is a popular drug for cancer treatment and life extension. The drug is made of macrolide compound that is used to coat coronary stent and prevent organ transplant rejection. The compound is also used to treat a lung disease known as lymphangioleiomyomatosis. The drug is useful when it comes to the inhibition of the B-cells and T-cells activation. It inhibits the activation of these cells by reducing the production rate of interleukin-2.
Perhaps, Dr. Mikhail Blagosklonny is one of the passionate advocates of the research on the use of rapamycin drug in cancer treatment. Apart from the hypothesis, the research done by Dr. Blagosklonny range from cellular and molecular biology to clinical investigation, which includes cell cycle and new anticancer strategies. With his research, Dr. Mikhail has managed to improve the state of art and technologies that are used in the study of cancer and its treatments. Visit Google Scholar for more info.